Gynecol Endocrinol. 2010 Dec;26(12):851-4. doi: 10.3109/09513590.2010.534612.
Over the past 50 years hormonal contraceptives have gradually developed to be cost-effective medical treatment modalities for primary and secondary therapy of endometriosis/adenomyosis. This is particularly true for the various estrogen/progestogen combinations as monophasic - particularly progestogen-dominant - preparations in cyclic, long-cyclic and continuous treatment forms. An alternative is the progestogen-only therapy used continuously. Therapeutic effects have been shown for peritoneal, ovarian and deep-infiltrating endometriosis as well as for adenomyosis. An individualized, medical long-term treatment concept to control endometriosis/adenomyosis-related symptoms, endometriosis/adenomyosis development and minimizing the recurrence rate needs to be further studied in women, who do not desire to become pregnant.
在过去的 50 年中，激素避孕药逐渐发展成为子宫内膜异位症/子宫腺肌病的主要和次要治疗的经济有效的医学治疗方法。对于各种雌激素/孕激素组合尤其如此，它们以单相 - 特别是孕激素优势 - 制剂的形式用于周期性、长周期和连续治疗形式。另一种选择是连续使用孕激素的孕激素疗法。已经证明了这种疗法对腹膜、卵巢和深部浸润性子宫内膜异位症以及子宫腺肌病的疗效。对于那些不希望怀孕的女性，需要进一步研究个体化、长期的医学治疗方案，以控制与子宫内膜异位症/子宫腺肌病相关的症状、子宫内膜异位症/子宫腺肌病的发展并最小化复发率。
